Testofen, a specialised Trigonella foenum-graecum seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a double-blind randomised clinical study

Amanda Rao, Elizabeth Steels, Warrick J. Inder, Suzanne Abraham & Luis Vitetta

To cite this article: Amanda Rao, Elizabeth Steels, Warrick J. Inder, Suzanne Abraham & Luis Vitetta (2016): Testofen, a specialised Trigonella foenum-graecum seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a double-blind randomised clinical study, The Aging Male, DOI: 10.3109/13685538.2015.1135323

To link to this article: http://dx.doi.org/10.3109/13685538.2015.1135323

Published online: 20 Jan 2016.

Submit your article to this journal

View related articles

View Crossmark data
Testofen, a specialised *Trigonella foenum-graecum* seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a double-blind randomised clinical study

Amanda Rao¹, Elizabeth Steels², Warrick J. Inder³, Suzanne Abraham¹, and Luis Vitetta¹,⁴

¹Department of Medicine, University of Sydney, Sydney, Australia, ²Integrated Health Group, Clinical Research, Brisbane, Australia, ³Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia, and ⁴Medlab Pty Ltd, Sydney, Australia

**Abstract**

This study examined the effect of Testofen, a specialised *Trigonella foenum-graecum* seed extract on the symptoms of possible androgen deficiency, sexual function and serum androgen concentrations in healthy aging males. This was a double-blind, randomised, placebo-controlled trial involving 120 healthy men aged between 43 and 70 years of age. The active treatment was standardised *Trigonella foenum-graecum* seed extract at a dose of 600 mg/day for 12 weeks. The primary outcome measure was the change in the Aging Male Symptom questionnaire (AMS), a measure of possible androgen deficiency symptoms; secondary outcome measures were sexual function and serum testosterone. There was a significant decrease in AMS score over time and between the active and placebo groups. Sexual function improved, including number of morning erections and frequency of sexual activity. Both total serum testosterone and free testosterone increased compared to placebo after 12 weeks of active treatment. *Trigonella foenum-graecum* seed extract is a safe and effective treatment for reducing symptoms of possible androgen deficiency, improves sexual function and increases serum testosterone in healthy middle-aged and older men.

**Keywords**

Ageing male syndrome, androgens, sexual function, testofen, testosterone, *Trigonella foenum-graecum*

**History**

Received 24 September 2015
Revised 13 December 2015
Accepted 19 December 2015
Published online 20 January 2016

**Introduction**

Testosterone concentrations decrease in men at a rate of 1–2% per year after the age of 40 [1–3]. This decrease varies considerably between individuals, relates to the accumulation of co-morbid conditions including weight gain [4–6] and may be due to a combination of reduced hypothalamic gonadotropin releasing hormone outflow, alterations in androgenic negative feedback and decreased responsiveness of testicular tissue [7,8]. This decline in testosterone is associated with decreased albumin and increased sex hormone binding globulin (SHBG), resulting in higher levels of serum testosterone binding to SHBG, which together decreases free (bioavailable) testosterone [9].

The clinical significance of a low or low-normal testosterone level in men is not well understood [10]. There is an association between decrease in serum testosterone in older men with reduction in sexual activity and desire, although causality is as yet undetermined [11]. There is also evidence that lower testosterone levels are linked with an increased risk of developing metabolic syndrome and cognitive decline [12,13]. In addition, other symptoms of deficiency may include muscle weakness, weight gain, increased abdominal fat, musculoskeletal changes and joint pain, hot flushes or sweating, sleep disturbances, insomnia, fatigue, depression, decreased body hair and skin alterations, and low bone mineral density. Depending upon the set of symptoms being experienced, a negative effect on quality of life as well as an impact on health and relationships may occur [14,15].

Testosterone also decreases in response to age-related physical changes such as weight gain, increased waist circumference and deterioration of general health associated with chronic disease such as diabetes, liver disease, and cardiovascular disease [16,17]. Medications such as opioids, glucocorticoids and anti-depressants may directly inhibit the hypothalamic-pituitary-testicular axis also resulting in decreased testosterone [18–20].

The combination of low testosterone and the array of the above symptoms is variably referred to as aging male syndrome (AMS), andropause, partial androgen deficiency of the aging male (PADAM), and late-onset hypogonadism (LOH) [15,21,22]. The prevalence is unknown, large-scale
studies suggest it may be as little as 2.1% in men aged 40–70 [23,24] but other clinical studies have reported that androgen deficiency affects 39% of men aged greater than 45 years [25].

Currently, testosterone replacement therapy is prescribed to men when they are clinically defined as androgen deficient. Testosterone replacement in men with established hypogonadism significantly increases lean body mass and decreases fat mass without an overall change in body weight and improves sexual function and cognition [15,26–28]. Overall, there are few large-scale clinical trials on the efficacy of testosterone therapy in the older male age group. Some studies suggest there are potential health risks including erythrocytosis and prostate cancer [22,29] while others have shown some beneficial, though short-lived effects [30].

There is limited research on the use of herbal medicines to improve male health, particularly to increase testosterone levels and support healthy sexual function. To date, there are no published human clinical studies using herbal medicines for symptoms associated with the age related decrease in androgens.

Earlier research suggested that *Trigonella foenum-graecum* seed extract had a positive effect on sexual health and quality of life [31], as well as demonstrating anabolic and androgenic activity in younger men [32]. It is thought that this positive effect was, at least, partly, due to increased testosterone, including free testosterone and that *Trigonella foenum-graecum* seed extract may also be an effective treatment for the symptoms of possible androgen deficiency in aging men. The basis for this androgenic activity may be due to the fact that *Trigonella foenum-graecum* seeds contain soluble steroidal saponins, specifically furostanol glycosides responsible for complexing cholesterol in the cell membrane [33,34]. Other studies that have shown that *Trigonella foenum-graecum* increases testosterone, and free testosterone suggest it may be an incomplete 5-alpha reductase and aromatase inhibitor [35].

The hypothesis was that the use of *Trigonella foenum-graecum* seed extract for 12 weeks as a therapy would reduce the symptoms of possible androgen decline, improve reported sexual function and increase serum testosterone in healthy middle-aged and older males.

**Methods**

**Study design**

This was a single-site, double-blind, randomised, short-duration (12 week) clinical trial utilising active and placebo arms to assess (i) the factors that influence testosterone concentrations and (ii) the effect of *Trigonella foenum-graecum* seed extract on symptoms of possible androgen deficiency, sexual function and serum hormone concentrations, particularly testosterone, in healthy aging males. It was conducted between February and November 2014 in Brisbane, Australia.

**Study population**

The study population included 120 healthy male subjects, aged 43–75 years, recruited through a trial recruitment database and public media. After preliminary screening via telephone, subjects were required to attend a pre-trial interview and provide written informed consent. Comprehensive screening was performed after an initial health assessment including lifestyle questions, current medications, medical history and a physical examination.

Potential subjects were excluded if they had any of the following: any condition which in the opinion of the investigator made the subject unsuitable for inclusion, diagnosed erectile dysfunction or any physical disability that may limit sexual function, had received any treatment/therapy (including testosterone or anabolic steroids) for any sexual disorder during last 6 months, were being prescribed anticoagulation therapy, were receiving levodopa for Parkinson’s disease or calcipotriene for psoriasis, were diagnosed with severe renal and/or hepatic insufficiency, were diagnosed with genital anatomical deformities, uncontrolled diabetes mellitus, had a history of spinal cord injury, major psychiatric disorder, and/or had any abnormal secondary sexual characteristics. They were also excluded if they were diagnosed with prostate cancer or benign prostatic hypertrophy, had an acute genitourinary disorder or history of genital surgery, if they had a current or past history of chronic alcohol and/or drug abuse or had a suspected or diagnosed chickpea allergy. If a potential subject was currently participating in another trial or had been in any other clinical trial during last 30 days they were also excluded from the present study.

**Outcomes**

**Primary**

**Symptoms of possible androgen deficiency.** The primary outcome measure was efficacy of treatment for symptoms using the Aging Male Symptom (AMS) questionnaire [36]. It consists of 17 questions in 3 sub-scales, psychological, somatic and sexual. These sub-scales as well as the total score were used to assess symptoms. Subjects completed the questionnaires pre-trial (baseline data), upon completion of weeks 6 (mid-trial) and 12 (completion).

**Secondary**

**Sexual function.** Sexual function was assessed using the Derogatis Interview for Sexual Functioning-Self Report (DISF-SR) questionnaire at baseline and week 12 (completion). It was designed to measure the quality of sexual function. The DISF-SR is a set of 21 questions, with 4 sub-domains: sexual fantasy (SC), sexual arousal (SA), sexual behaviours (SB) and orgasm (O) [37]. The DISF-SR Sexual sub-domain asks specifically about the frequency of morning erections and the Sexual Drive/Relationship sub-domain contained a question regarding the frequency of sexual intercourse.

**Serum sex hormone concentrations.** Secondary outcomes included serum total and calculated free testosterone (Sodergard equation, [38]), sex hormone binding globulin (SHBG), DHEA-S, androstenedione, oestradiol and prolactin. The subjects had blood drawn in the morning after an
overnight fast at baseline, 6 weeks (mid-trial) and 12 weeks (completion). Analysis was conducted at Queensland Medical Laboratories (QML), Brisbane, Australia by chemiluminescent immunoassay (CLIA).

Other outcomes
Sleep quality was assessed using the Pittsburgh Sleep Index (PSI) [39]. The Multi-dimensional Fatigue Index (MFI-20) was used to assess fatigue. The MFI-20 provides a total score for fatigue and also includes the individual domains of general, emotional, physical, mental health and vigour as separate aspects to fatigue [40]. Physical activity was measured using the International Physical Activity questionnaire (IPAQ) [41].

Other physical health parameters and anthropometric measurements (weight, height, waist, hip, grip strength) were also performed. Red and white blood cells, electrolyte and liver function and lipid profile were also measured at baseline and 12 weeks.

Randomisation and blinding
Randomisation of the products was performed independently of the investigators using Random Allocation Software, version 1.0, May 2004. The investigational products were delivered to the investigators in trial product containers that were identical in function and appearance, marked from 001 to 0120. Once enrolled in the trial, subjects were randomly allocated to the next available number in the sequence, either the placebo comparator group (n = 60) or the active intervention group (n = 60). Investigators were blinded to the randomisation and therefore blinded to which subjects were allocated to the active and treatment arms.

Subjects were monitored for compliance with the protocol by a combination of telephone and email communications. The doses taken were assessed by number of returned tablets at completion of the study.

Statistical methods
Sample size
Sample size was calculated on the primary outcome, the AMS total score. Based on a power of 80%, a sample size of 48 subjects in each treatment group was required, with 60 subjects recruited to account for potential withdrawals.

Analysis
The primary outcome endpoint (AMS questionnaire total and domain scores) at baseline, week 6 and week 12 was analysed using a two way repeated measures ANOVA for treatment and time. The DISF-SR total and domain scores were assessed for statistical difference within-groups (change from baseline) and between groups by t-tests. Change in pathology data was assessed using a two way repeated measures ANOVA for treatment and domain scores) at baseline, week 6 and week 12 was analysed.

Analysis was conducted using Pearson Correlation Co-efficient. Effect sizes are reported as Eta squared (\(\eta^2\)).

The study was carried out according to the principles expressed in the Declaration of Helsinki and was approved by the Queensland Clinical Trials Network Human Research Ethics Committee (QCTN) No: 2013002. The trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) No: 12613000925741.

Results
Demographics
Initially, 120 men were enrolled and commenced treatment in the study, with 111 completing the study; 55 in the active treatment group and 56 in the placebo group (Figure 1). There were no significant differences between the active treatment and placebo groups for age, anthropometric measures and the lifestyle factors (Table 1). All men had a sexual partner for the duration of the study.

Total cholesterol, triglycerides, LDL and HDL were not significantly different between the two groups. All men had normal full blood count, renal and liver function and prostate specific antigen (PSA) levels within healthy reference range for their age. The mean serum total testosterone and free testosterone concentrations represented the lower end of the healthy reference range for men in this age group (Table 1).

Relationship between age, BMI and health indices
There was no correlation between age and total testosterone although there was a weak negative correlation between age and free testosterone (\(r = -0.196, p = 0.042\)). A negative correlation was found between BMI and both total testosterone \((r = -0.304, p = 0.001)\) and free testosterone \((r = -0.279, p = 0.003)\). Total testosterone was positively correlated with HDL cholesterol \((r = 0.237, p = 0.017)\) but not with total or LDL cholesterol. There was no correlation between testosterone and the AMS score except on the somatic sub-domain \((r = -0.310, p = 0.001)\). There was no correlation between total or free testosterone, sexual function (measured by the DISF-SR), sleep or physical activity in this group of men.

Treatment with Trigonella foenum-graecum seed extract
Effect on general health parameters
There was no change in BMI, waist/hip ratios or grip strength during the course of the study for either the active treatment or the placebo groups (Table 2).

There were no significant changes in sleep patterns, the type or duration of physical activity or fatigue score in either the active treatment or the placebo group.

Effect on symptoms of possible androgen deficiency
The mean AMS total score and subscores for the active and placebo treatment groups at baseline, 6 weeks and 12 weeks are shown in Figure 2. There was no significant difference between the groups at baseline.

Repeated measures ANOVA showed a significant difference across time \(F(2,216) = 8.6, p < 0.001, \eta^2 = 0.073\) and a significant difference between groups \(F(1,108) = 6.4, p = 0.013, \eta^2 = 0.056\) for total AMS Score.

There were also significant differences for the somatic and sexual sub-scores across time \(F(2,216) = 9.1, p < 0.001, \eta^2 = 0.073\) and \(F(2,216) = 4.2, p = 0.017, \eta^2 = 0.038\) for the somatic subscore and \(F(2,216) = 5.3, p = 0.006, \eta^2 = 0.047\) for the sexual subscore.

There were also no significant differences between the groups at baseline for the somatic sub-scores.
\( \eta^2 = 0.078 \) and \( F(2,216) = 6.3, \ p = 0.002, \ \eta^2 = 0.055 \) respectively and between treatment groups \( F(1,108) = 4.8, \ p = 0.03, \ \eta^2 = 0.043 \) and \( F(1,108) = 7.1, \ p = 0.009, \ \eta^2 = 0.062 \). There was a significant difference across time for the psychology sub-score \( F(2,216) = 4.9, \ p < 0.008, \ \eta^2 = 0.043 \) but no treatment effect \( F(1,108) = 2.6, \ p < 0.11 \).

Effect on sexual function

The effect of \( Trigonella foenum-graecum \) seed extract on sexual function was assessed using the DISF-SR at baseline and at week 12. There was a significant change in the total score in active treatment group \( (p = 0.006) \) after treatment. Analysis of the sub-domains showed a significant difference in the sub-domains of Sexual Arousal \( (p = 0.001) \) and Sexual Drive/Relationship \( (p = 0.007) \), but there were no changes in the sub-domains of Sexual Cognition, Sexual Behaviour or Orgasm. There were no changes observed in the placebo group before or after treatment in the total score or any sub-domain (Table 3).

At baseline, both groups reported an average of one erection per week but this increased significantly to 2–3 per week \( (p = 0.001) \) in the active treatment group. At baseline, both groups reported sexual activity of approximately 1–2 times per month, this increased significantly to almost once a week \( (p = 0.004) \) in the active treatment group by week 12. These results were consistent with the positive results reported in the sexual function sub-domain of the AMS questionnaire “Which of the following symptoms apply to you at this time”, in particular, questions 16 “Decrease in the number of morning erections” and question 17 “Decrease in sexual desire/libido” (Figure 3).

Effect on sex hormones, liver function and lipids

The results of this study showed that there were no changes in levels of DHEA-S, androstenedione, oestradiol, SHBG or prolactin in either group during the 12 weeks of the study (Table 4). There were no significant changes in liver function, total, LDL or HDL cholesterol, or triglycerides, in either group after 12 weeks.

Total testosterone levels were similar between both groups at baseline. There was a small but significant difference in the change from baseline \( (\Delta) \) values between the active treatment and placebo groups for testosterone and calculated free testosterone at week 12. Further, bivariate analysis of covariance was calculated with a Bonferroni adjustment using BMI and age as the covariate factors and both total
testosterone $F(1,91) = 13.8, p < 0.001$, $\eta^2 = 0.134$ and free testosterone $F(1,91) = 10.8, p = 0.002$, $\eta^2 = 0.106$ remained significant (Table 4).

**Safety data**

The routine hematological and biochemical parameters were similar at baseline and after 12 weeks of treatment. The treatment was well tolerated. There were no serious adverse effects. There were five minor adverse reactions reported, three in the active treatment group (increased frequency of headaches (2), dizziness (1) and two in the placebo group (nausea (1), increased asthma symptoms (1), however these may not have been attributed to the treatment.

**Discussion**

This is the first published study of a *Trigonella foenum-graecum* seed extract in the treatment of symptoms of possible androgen deficiency in aging men. Symptom severity was measured by the aging males symptoms scale (AMS), which was developed as an indication of the severity of symptoms [42]. The results of this study demonstrate that *Trigonella foenum-graecum* (Testofen) seed extract significantly reduces symptom severity in the aging male. The most significant changes observed were in the somatic and sexual function domains of the AMS.

Sexual function was also assessed using the DISF-SR sexual function questionnaire, and this was found to compare

### Table 1. Subject demographics at baseline.

<table>
<thead>
<tr>
<th></th>
<th>Total ($n = 111$)</th>
<th>Active ($n = 56$)</th>
<th>Placebo ($n = 55$)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>55.6 (7.2)</td>
<td>54.8 (6.9)</td>
<td>56.4 (7.4)</td>
</tr>
<tr>
<td>Range</td>
<td>40–75</td>
<td>43–75</td>
<td>40–74</td>
</tr>
<tr>
<td><strong>Number of children</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>0.7</td>
<td>0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>Range</td>
<td>0–4</td>
<td>0–3</td>
<td>0–4</td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (Number, %)</td>
<td>8 (7.2%)</td>
<td>5 (8.9%)</td>
<td>3 (5.5%)</td>
</tr>
<tr>
<td>No (Number, %)</td>
<td>103 (92.8%)</td>
<td>51 (91.1)</td>
<td>52 (94.5%)</td>
</tr>
<tr>
<td><strong>Alcohol intake</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (Number, %)</td>
<td>39 (34.5%)</td>
<td>22 (39.3%)</td>
<td>17 (31.0%)</td>
</tr>
<tr>
<td>Social (Number, %)</td>
<td>72 (65.5%)</td>
<td>34 (60.7%)</td>
<td>38 (69.0%)</td>
</tr>
<tr>
<td><strong>Exercise Patterns</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None (Number, %)</td>
<td>66 (59.5%)</td>
<td>34 (60.7%)</td>
<td>32 (58.2%)</td>
</tr>
<tr>
<td>Regular (Number, %)</td>
<td>45 (40.5%)</td>
<td>22 (39.3%)</td>
<td>23 (41.8%)</td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Testosterone nmol/L (SD)</td>
<td>12.8 (4.8)</td>
<td>12.3 (4.4)</td>
<td>13.2 (5.1)</td>
</tr>
<tr>
<td>Free Testosterone (calculated) pmol/L (SD)</td>
<td>247 (82)</td>
<td>241 (69)</td>
<td>254 (94)</td>
</tr>
<tr>
<td>SHBG nmol/L (SD)</td>
<td>35.6 (17.2)</td>
<td>34.5 (14.6)</td>
<td>36.6 (19.5)</td>
</tr>
<tr>
<td>DHEA sulphate pmol/L (SD)</td>
<td>3.8 (2.1)</td>
<td>3.6 (1.8)</td>
<td>3.9 (2.4)</td>
</tr>
<tr>
<td>Androstenedione nmol/L (SD)</td>
<td>5.6 (3.4)</td>
<td>5.6 (3.9)</td>
<td>5.6 (3.4)</td>
</tr>
<tr>
<td>Oestradiol pmol/L (SD)</td>
<td>100.5 (38.9)</td>
<td>100.2 (43.2)</td>
<td>100.7 (34.4)</td>
</tr>
<tr>
<td>Prolactin ug/L (SD)</td>
<td>7.2 (2.9)</td>
<td>7.2 (2.8)</td>
<td>7.3 (2.9)</td>
</tr>
<tr>
<td>PSA(µg/L)</td>
<td>1.1 (1.4)</td>
<td>1.1 (1.1)</td>
<td>1.1 (1.9)</td>
</tr>
<tr>
<td>Total Cholesterol mmol/L (SD)</td>
<td>5.5 (1.1)</td>
<td>5.6 (1.0)</td>
<td>5.4 (1.1)</td>
</tr>
<tr>
<td>Triglycerides mmol/L (SD)</td>
<td>1.4 (0.9)</td>
<td>1.4 (1.1)</td>
<td>1.4 (0.7)</td>
</tr>
<tr>
<td>HDL mmol/L (SD)</td>
<td>1.3 (0.4)</td>
<td>1.4 (0.5)</td>
<td>1.3 (0.3)</td>
</tr>
<tr>
<td>LDL mmol/L (SD)</td>
<td>3.0 (1.0)</td>
<td>3.1 (0.9)</td>
<td>3.0 (1.0)</td>
</tr>
<tr>
<td>HDL/LDL ratio (SD)</td>
<td>4.5 (1.4)</td>
<td>4.4 (1.5)</td>
<td>4.5 (1.3)</td>
</tr>
</tbody>
</table>

No significant differences active versus placebo in any of the above.

### Table 2. Anthropometric parameters in the active treatment and placebo groups at baseline, week 6 and week 12.

<table>
<thead>
<tr>
<th></th>
<th>Active ($n = 56$)</th>
<th>Placebo ($n = 54$)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean BMI kg/m$^2$ (SD)</td>
<td>30.1 (5.1)</td>
<td>29.3 (4.4)</td>
</tr>
<tr>
<td>Mean waist/hip ratio (SD)</td>
<td>1.0 (0.04)</td>
<td>1.0 (0.03)</td>
</tr>
<tr>
<td>Average strength left hand kg(SD)</td>
<td>43.3 (8.1)</td>
<td>42.7 (8.3)</td>
</tr>
<tr>
<td>Average strength right hand kg</td>
<td>44.7 (8.5)</td>
<td>44.3 (8.0)</td>
</tr>
</tbody>
</table>

**Discussion**

This is the first published study of a *Trigonella foenum-graecum* seed extract in the treatment of symptoms of possible androgen deficiency in aging men. Symptom severity was measured by the aging males symptoms scale (AMS), which was developed as an indication of the severity of symptoms [42]. The results of this study demonstrate that *Trigonella foenum-graecum* (Testofen) seed extract significantly reduces symptom severity in the aging male. The most significant changes observed were in the somatic and sexual function domains of the AMS.

Sexual function was also assessed using the DISF-SR sexual function questionnaire, and this was found to compare
well with the sexual function domain of the AMS questionnaire. It showed that treatment with *Trigonella foenum-graecum* seed extract resulted in a significant improvement in sexual functioning, including desire, arousal and frequency of morning erections. These results are supported by an earlier study of younger men using the same *Trigonella foenum-graecum* seed extract which was found to have a positive effect on sexual function in men who were experiencing low libido [31].

Furthermore, this study has demonstrated that this particular *Trigonella foenum-graecum* seed extract results in small but statistically significant increases in serum total and free testosterone. This effect was independent of age, as increases were observed in all age brackets from 40 years to 70 years. These results provide a potential mechanism for the positive effects on somatic and sexual function observed in this study. It is hypothesised that the reduction in severity of symptoms and increased somatic and sexual function was directly or indirectly related to the increased serum testosterone.

This is supported by an earlier study of another extract in younger exercising men that demonstrated that *Trigonella foenum-graecum* decreased body fat and increased total and free testosterone [32]. Potential mechanisms by which *Trigonella foenum-graecum* may increase serum testosterone include stimulation of pulsatile GnRH/LH, increased testicular sensitivity to LH, and increased testosterone synthesis or reduced testosterone catabolism. However, further study still needs to be undertaken before a comprehensive mechanism of action can be proposed.

A similar pattern of reduced symptoms and improved sexual function is also observed in men treated directly with

---

**Figure 2.** Total and sub-domain scores of the aging male symptom questionnaire (AMS) for active treatment and placebo groups at baseline, week 6 and week 12. Data are expressed as mean ± SD.

**Table 3.** Assessment of changes in sexual function in active treatment group and placebo group at baseline and 12 weeks.

<table>
<thead>
<tr>
<th>DISF-SR</th>
<th>Active Mean (SD) (<em>n</em> = 56)</th>
<th>Placebo Mean (SD) (<em>n</em> = 55)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 12</td>
</tr>
<tr>
<td>Total score</td>
<td>66.2 (25.0)</td>
<td>76.3 (30.7)*</td>
</tr>
<tr>
<td>Sexual cognition</td>
<td>20.8 (9.7)</td>
<td>22.1 (9.5)</td>
</tr>
<tr>
<td>Sexual arousal</td>
<td>12.9 (7.4)</td>
<td>16.8 (9.1)**</td>
</tr>
<tr>
<td>Sexual behaviour</td>
<td>11.0 (6.3)</td>
<td>12.3 (7.1)</td>
</tr>
<tr>
<td>Orgasm</td>
<td>10.6 (5.2)</td>
<td>12.3 (6.4)</td>
</tr>
<tr>
<td>Sexual drive/Relationship</td>
<td>11.1 (3.1)</td>
<td>12.8 (4.3)*</td>
</tr>
</tbody>
</table>

* *p* < 0.01, ** *p* = 0.001 compared to baseline.
While the AMS score consists of age-related and testosterone-associated decline in health parameters in males, it has been considered as a potential predictor of androgen status in men. Previous research had found a significant correlation of AMS scores with lowered free testosterone [44,45]. However, a number of other studies failed to reveal a correlation of the questionnaire results with serum testosterone levels [46,47]. A recent study by Zengerling et al. [48] demonstrated that AMS total score is not a predictor of total or free testosterone levels or hypogonadism but there was a correlation with the sexual and somatic sub-scores, a result that was also observed in this current study. This suggests that the changes in testosterone, while linked to sexual function and mood in men, is not responsible for all aspects of aging.

There was only a weak correlation between free testosterone levels and age. Instead, total testosterone levels and free testosterone levels were inversely related to BMI. This is consistent with recent studies indicating that in generally healthy men, there was no decrease in the mean total testosterone level with increasing age, yet statistically and clinically negative correlation between testosterone and BMI and positive correlation between testosterone and fitness [49]. While it has been suggested that there is an age-related decline in testosterone due to altered function both centrally (at the level of the hypothalamic-pituitary unit) and at the level of the testis [8], other data indicate that the decline in testosterone is more associated with the accumulation of co-morbidities, particularly weight gain [4–6]. The EMAS study of 3320 men aged between 40 and 79 years, showed that the aging-related decline of testosterone has great individual variability, with about 20% of men over 60 years having serum testosterone in the upper normal range of young men, and about 20% being below the reference range. This research has also established that testosterone in a man with BMI<30 is, on average, 30% lower than that of a man with BMI>25, at any age, which is more than the purely age-dependent decrease between 40 and 80 years [50]. The increase in serum testosterone observed across our study in the active treatment group occurred independently of any change in BMI.

### Table 4. Hormone levels for active treatment and placebo groups at baseline, week 6 and week 12.

<table>
<thead>
<tr>
<th></th>
<th>Mean (SD) Range</th>
<th>Active Treatment group (n = 47)</th>
<th>Placebo group (n = 50)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 6</td>
<td>Week 12</td>
</tr>
<tr>
<td>Testosterone [nmol/L]</td>
<td>12.3 (4.4)</td>
<td>12.9 (4.9)</td>
<td>13.8* (5.1) (p = 0.001)</td>
</tr>
<tr>
<td>Calculated free Testosterone [pmol/L]</td>
<td>241 (68.9)</td>
<td>245 (80.6)</td>
<td>264* (78.9) (p = 0.002)</td>
</tr>
<tr>
<td>SHBG [nmol/L]</td>
<td>34.5 (14.6)</td>
<td>36.7 (15.3)</td>
<td>37.4 (15.6)</td>
</tr>
<tr>
<td>Oestradiol [pmol/L]</td>
<td>100.2 (43.2)</td>
<td>101.9 (44.1)</td>
<td>107.1 (45.3)</td>
</tr>
<tr>
<td>Prolactin [μg/L]</td>
<td>7.2 (2.8)</td>
<td>7.4 (3.4)</td>
<td>7.0 (2.7)</td>
</tr>
<tr>
<td>Androstenedione [nmol/L]</td>
<td>5.6 (3.9)</td>
<td>4.9 (2.8)</td>
<td>5.0 (3.0)</td>
</tr>
<tr>
<td>DHEA-S [μmol/L]</td>
<td>3.6 (1.8)</td>
<td>3.7 (1.8)</td>
<td>3.7 (1.8)</td>
</tr>
</tbody>
</table>

*Statistically significant – ANCOVA (Age and BMI as covariates.)
Neither AMS nor serum testosterone was correlated with regular exercise (deemed more than 3 days per week). Interestingly, a previous study on a larger population of 421 men had shown that psychological, somatic and general scores symptoms, as well as their severity were lower among those subjects who reached the current recommendations for physical activity during leisure and commuting time [51].

The MFI scale was used to assess individual components of fatigue including physical fatigue, mental fatigue, motivation and activity. As with physical activity, there were no changes in fatigue noted as a result of the treatment. The smaller sample size, time frame and possibly the subject age group may have had limitations to observing any differences. Earlier studies with testosterone gel have shown that sex hormone levels, physical complaints, depression, sexuality and life satisfaction, and low total and free testosterone are associated with reduced motivation [52] and in an observational 6 month study using testosterone gel, significant improvements in fatigue scores were observed [53].

Furthermore, in this study cohort, testosterone levels were positively correlated with HDL cholesterol. There were no changes observed in other hormones, DHEA-S, androstenedione, oestradiol or liver function after treatment with *Trigonella foenum-graecum* seed extract. The herbal medicine was well tolerated, although was associated with headache in <5% of subjects, an effect also observed in the earlier study [31].

Recommendations have been published for the diagnosis, treatment and monitoring of hypogonadism in men [54]. In this document, a relatively high threshold for total testosterone of <12.1 nmol/L was suggested to classify hypogonadism. Further long-term studies are awaited to establish clear indications for and long-term safety of testosterone therapy in men with low or borderline testosterone concentrations in the absence of organic hypothalamic-pituitary or testicular pathology [8]. The use of herbal medicine such as extract of *Trigonella foenum-graecum* which has in this study shown efficacy in improving symptoms, may become an alternative for symptomatic men where low or borderline testosterone is associated with obesity, chronic disease and mood disorder rather than organic hypothalamic–pituitary–testicular axis pathology. However, further studies are needed to establish its long-term safety and efficacy.

In conclusion, this extract of *Trigonella foenum-graecum* seed was shown to be safe and effective, reducing symptoms of possible androgen deficiency, improving sexual function and increasing serum testosterone in healthy middle-aged and older men.

**Trial registration**

The trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) with Trial ID. ACTRN No: 12613000925741 and can be accessed on the ANZCTR website.

**Acknowledgements**

We would like to thank Queensland Clinical Trials Network (QCTN) for providing the ethics committee review.

**Declaration of interest**

The investigational products and funding were supplied by Gencor Pacific, Hong Kong.

**References**